These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model. Islam K; Sime FB; Wallis SC; Bauer MJ; Naicker S; Won H; Zowawi HM; Choudhury MA; Shirin T; Habib ZH; Harris PNA; Flora MS; Roberts JA Antimicrob Agents Chemother; 2022 Sep; 66(9):e0016222. PubMed ID: 35924928 [TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic Heffernan AJ; Sime FB; Sarovich DS; Neely M; Guerra-Valero Y; Naicker S; Cottrell K; Harris P; Andrews KT; Ellwood D; Wallis SC; Lipman J; Grimwood K; Roberts JA Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32660986 [TBL] [Abstract][Full Text] [Related]
6. Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates. Karabasevic N; Roberts JA; Stronach L; Naicker S; Wallis SC; Sjövall F; Sime F Antimicrob Agents Chemother; 2022 May; 66(5):e0214021. PubMed ID: 35389238 [TBL] [Abstract][Full Text] [Related]
7. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610 [TBL] [Abstract][Full Text] [Related]
8. Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Farrington N; Dubey V; Johnson A; Horner I; Stevenson A; Unsworth J; Jimenez-Valverde A; Schwartz J; Das S; Hope W; Darlow CA mBio; 2024 Feb; 15(2):e0316523. PubMed ID: 38236031 [TBL] [Abstract][Full Text] [Related]
9. The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection. Wang Y; Li C; Wang J; Bai N; Zhang H; Chi Y; Cai Y Microbiol Spectr; 2022 Oct; 10(5):e0146822. PubMed ID: 36102678 [TBL] [Abstract][Full Text] [Related]
10. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling. Yadav R; Bulitta JB; Nation RL; Landersdorfer CB Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448 [TBL] [Abstract][Full Text] [Related]
11. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141 [TBL] [Abstract][Full Text] [Related]
12. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846 [TBL] [Abstract][Full Text] [Related]
13. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model. Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301 [TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study. Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109 [TBL] [Abstract][Full Text] [Related]
15. Metabolomics reveals the mechanism of action of meropenem and amikacin combined in the treatment of Yang H; Huang Z; Yue J; Chen J; Yu M; Qu C Front Cell Infect Microbiol; 2023; 13():1327452. PubMed ID: 38116135 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380 [TBL] [Abstract][Full Text] [Related]
18. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. Lim TP; Lee W; Tan TY; Sasikala S; Teo J; Hsu LY; Tan TT; Syahidah N; Kwa AL PLoS One; 2011; 6(12):e28177. PubMed ID: 22162759 [TBL] [Abstract][Full Text] [Related]
19. Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Zhang X; Wang Y; Li S; Xie F; Yi H Antimicrob Agents Chemother; 2024 Mar; 68(3):e0154123. PubMed ID: 38319075 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Cappelletty DM; Kang SL; Palmer SM; Rybak MJ Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]